Hims & Hers Health and Novo Nordisk: from GLP-1 chaos to “sell it on our platform”
TL;DR
Quick Summary
- On March 9, 2026, reports said Novo Nordisk may sell its weight-loss drugs via Hims & Hers’ platform, signaling a possible truce after legal conflict.
- A branded-drug channel could make Hims’ weight-loss growth feel more sustainable than relying on compounded alternatives.
- Hims’ 2026 outlook is already sizable: $2.7B–$2.9B revenue guidance and $300M–$375M adjusted EBITDA guidance (issued with 2025 results).
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
